NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free SABS Stock Alerts $4.54 +0.32 (+7.58%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.22▼$4.6750-Day Range$4.17▼$6.0852-Week Range$3.66▼$14.50Volume4,771 shsAverage Volume25,000 shsMarket Capitalization$23.75 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get SAB Biotherapeutics alerts: Email Address SAB Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside120.3% Upside$10.00 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.64) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.35 out of 5 starsMedical Sector335th out of 939 stocksBiological Products, Except Diagnostic Industry49th out of 158 stocks 3.3 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, SAB Biotherapeutics has a forecasted upside of 120.3% from its current price of $4.54.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SAB Biotherapeutics has recently decreased by 15.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 2.8 News and Social Media Coverage News SentimentSAB Biotherapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for SABS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.95% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.82% of the stock of SAB Biotherapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($4.64) to ($2.96) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About SAB Biotherapeutics Stock (NASDAQ:SABS)SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.Read More SABS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Stock News HeadlinesMarch 29, 2024 | globenewswire.comSAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 28, 2024 | americanbankingnews.comSAB Biotherapeutics (SABS) Set to Announce Quarterly Earnings on FridayMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 25, 2024 | markets.businessinsider.comSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock DropsMarch 25, 2024 | globenewswire.comSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentFebruary 23, 2024 | globenewswire.comSAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.February 2, 2024 | marketwatch.comSAB Biotherapeutics Names Samuel Reich Chief ExecutiveFebruary 2, 2024 | markets.businessinsider.comSAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEOFebruary 2, 2024 | finance.yahoo.comSAB Biotherapeutics Announces Executive Leadership ChangeJanuary 24, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 23, 2024 | finance.yahoo.comSAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)January 5, 2024 | finance.yahoo.comIndividual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last weekJanuary 3, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitJanuary 2, 2024 | finance.yahoo.comSAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitDecember 8, 2023 | finance.yahoo.comHere's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock NowDecember 1, 2023 | msn.comVerifyMe And 3 Other Stocks Under $2 Insiders Are BuyingNovember 29, 2023 | finance.yahoo.comSAB Biotherapeutics Starts Human Clinical Trial of Diabetes TreatmentNovember 29, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In AustraliaNovember 29, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNovember 20, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNovember 20, 2023 | finance.yahoo.comSAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNovember 14, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNovember 14, 2023 | msn.comSAB Biotherapeutics GAAP EPS of -$0.10See More Headlines Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/21/2023Today3/28/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+120.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,740,000.00 Net Margins-664.68% Pretax Margin-664.04% Return on Equity-120.36% Return on Assets-69.17% Debt Debt-to-Equity Ratio0.23 Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$23.90 million Price / Sales0.99 Cash FlowN/A Price / Cash FlowN/A Book Value$7.22 per share Price / Book0.63Miscellaneous Outstanding Shares5,230,000Free Float3,874,000Market Cap$23.74 million OptionableNot Optionable Beta0.78 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Samuel J. Reich (Age 49)CEO & Executive Chairman Comp: $376.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President & Director Comp: $430.62kMs. Christine E. Hamilton M.B.A. (Age 68)Co-Founder & Independent Director Comp: $25kDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Executive VP & Chief Medical Officer Comp: $486.96kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverMr. Michael George King Jr. (Age 63)EVP & CFO Dr. Christoph Bausch M.B.A. (Age 53)Ph.D., Executive VP & COO Dr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsAcorda TherapeuticsNASDAQ:ACORCurisNASDAQ:CRISAIM ImmunoTechNYSE:AIMZIVO BioscienceNASDAQ:ZIVOPharmaCyte BiotechNASDAQ:PMCBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 19,194 shares on 3/11/2024Ownership: 19.047%BVF Inc. ILBought 9,178,282 shares on 2/15/2024Ownership: 175.426%Vanguard Group Inc.Bought 19,194 shares on 2/15/2024Ownership: 19.039%Pathstone Holdings LLCBought 506,513 shares on 2/14/2024Ownership: 9.685%Kestra Advisory Services LLCBought 67,000 shares on 2/14/2024Ownership: 1.683%View All Insider TransactionsView All Institutional Transactions SABS Stock Analysis - Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SABS shares. View SABS analyst ratings or view top-rated stocks. What is SAB Biotherapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 12 month target prices for SAB Biotherapeutics' shares. Their SABS share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 120.3% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts. How have SABS shares performed in 2024? SAB Biotherapeutics' stock was trading at $0.6875 on January 1st, 2024. Since then, SABS stock has increased by 560.4% and is now trading at $4.54. View the best growth stocks for 2024 here. When is SAB Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our SABS earnings forecast. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) announced its quarterly earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The business had revenue of $0.09 million for the quarter. SAB Biotherapeutics had a negative net margin of 664.68% and a negative trailing twelve-month return on equity of 120.36%. Who are SAB Biotherapeutics' major shareholders? SAB Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (175.49%), BVF Inc. IL (175.43%), Commodore Capital LP (35.02%), Vanguard Group Inc. (19.05%), Vanguard Group Inc. (19.04%) and Pathstone Holdings LLC (9.68%). Insiders that own company stock include Christine E Hamilton, Eddie Joe Sullivan, Michael King and Samuel J Reich. View institutional ownership trends. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SABS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.